The United States glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 10.25 Billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity along with the robust regulatory support in the region. The market is anticipated to grow at a CAGR of 8.20% during the forecast period of 2025-2034, with the values likely to reach USD 22.54 Billion by 2034.
Base Year
Historical Period
Forecast Period
About 1 in 10 people in the United States are living with diabetes, with 90% to 95% of them having type 2 diabetes. The rising prevalence of diabetes in the region is expected to boost the market demand in the forecast period.
The increasing expansion of GLP-1 therapies into new indications and rising consumer awareness are projected to elevate the United States glucagon-like peptide-1 (GLP-1) agonists market value.
In December 2024, the FDA approved a generic version of liraglutide (Victoza) for type 2 diabetes, following a generic exenatide (Byetta) approval in November. The rising generic GLP-1 approvals are a major market trend.
Value in USD Billion
2025-2034
United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Outlook
*this image is indicative*
The United States is considered the largest and fastest-growing market for glucagon-like peptide-1 (GLP-1) receptor agonists, owing to the rising prevalence of obesity and type 2 diabetes. The increasing demand for advanced weight loss and diabetes treatments is making GLP-1 drugs like Ozempic, Wegovy, and Mounjaro popular among both patients and healthcare providers. The growing regulatory approval for new GLP-1-based drugs is a significant market trend. Additionally, the expanding clinical trials and increasing insurance coverage are poised to boost market growth over the forecast period.
Rising Prevalence of Diabetes to Support Market Growth
According to the Centers for Disease Control and Prevention (CDC), about 1 in 10 people in the United States are affected by diabetes, accounting for more than 38 million Americans. It is also reported that 90% to 95% of them suffer from type 2 diabetes. The rising diabetes cases are increasing demand for GLP-1 receptor agonists like Ozempic and Mounjaro. Moreover, ongoing drug innovation and rising investments are expected to further expedite the market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Segmentation Based on Drugs to Witness Substantial Growth
Based on the drugs, the United States market is segmented into dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. Semaglutide holds a significant market share due to its established efficacy and availability of multiple formulations (Ozempic, Wegovy, Rybelsus). On the other hand, dulaglutide is a once-weekly injectable GLP-1 agonist used for type 2 diabetes management. It remains a popular alternative due to its convenience and cardiovascular benefits.
In the United States, the Northeast and West Coast regions have high adoption rates as a result of better healthcare access and widespread insurance coverage for GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. The Midwest and Southern states are witnessing substantial obesity and type 2 diabetes rates, which is fuelling the market demand in the region. Further, the expansion of pharmaceutical manufacturing facilities in states like North Carolina and Indiana is anticipated to address GLP-1 drug shortages and elevate the market value.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly is rapidly expanding its share in the United States market for GLP-1, with Mounjaro (tirzepatide) witnessing high demand for both diabetes and weight management. The company is investing substantially in new manufacturing plants in the region to scale up production and address ongoing GLP-1 drug shortages.
Sanofi is strategically strengthening its presence in the United States glucagon-like peptide-1 (GLP-1) agonists market, focusing on partnerships and pipeline expansion to compete with other key players like Novo Nordisk and Eli Lilly. The company is investing in R&D to develop novel GLP-1 formulations, particularly in once-weekly and oral therapies.
Novo Nordisk is one of the dominating players in the market, with Wegovy and Ozempic experiencing growing demand. To address drug shortages, the company is expanding production facilities and exploring additional supply chain improvements. Novo Nordisk is also partnering with U.S. healthcare providers to increase awareness and accessibility of GLP-1 therapies for obesity treatment.
AstraZeneca is shifting focus toward GLP-1 combination therapies in the United States, aiming to integrate GLP-1 drugs with cardiovascular and kidney disease treatments. The company is conducting new clinical trials on dual-action metabolic drugs that could complement GLP-1 receptor agonists.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share